BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.18.3.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:http://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20260101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20270323
DTEND;VALUE=DATE:20270326
DTSTAMP:20261112T123227Z
CREATED:20261112T123227Z
LAST-MODIFIED:20261112T123227Z
UID:44751-1805760000-1806019199@www.pharmajournalist.com
SUMMARY:7th Operationalize: Expanded Access Programs Summit
DESCRIPTION:The 7th Operationalize: Expanded Access Programs Summit returns at a pivotal moment as Expanded Access Programs evolve beyond a purely operational function to become a strategic component of patient access\, evidence generation\, post-trial planning\, and commercial readiness. As organizations expand access into new global markets and face growing expectations around real-world data\, patient continuity\, and reimbursement transitions\, EAP leaders are under increasing pressure to build scalable\, sustainable\, and patient-centric programs. \nAs the industry’s leading forum dedicated to Expanded Access\, this meeting brings together pharma\, biotech\, patient advocacy\, and access leaders to address the most pressing challenges shaping the future of global patient access\, including: \n\nStrengthening global post-trial access strategies to ensure long-term patient continuity while navigating regional regulatory and reimbursement complexities\nLeveraging real-world data generated through Expanded Access to support clinical development\, regulatory strategy\, and future market access decisions\nNavigating complex global access pathways across established and emerging markets while adapting programs to diverse healthcare systems and local requirements\nBuilding sustainable and scalable EAP models through improved governance\, regulatory intelligence\, operational frameworks\, and digital innovation\n\nWhat to Expect: \n\n150+ Pharma\, Biotech & Patient Access Leaders\n20+ Expert Speakers from Takeda\, Regeneron\, Alexion\, Alnylam\, Merck\, Sanofi & More\nInteractive Regional Networking & Peer Benchmarking Sessions\nDedicated Workshops Covering EAP Strategy\, Operations & Post-Trial Access\nLive Problem-Solving Discussions & Access Insights Poster Exchanges\n\nBringing together leaders responsible for medical affairs\, patient access\, clinical operations\, regulatory strategy\, and late-phase development\, this industry-led summit offers a unique opportunity to benchmark approaches\, share practical lessons\, and build meaningful connections with peers navigating the same challenges. \nBy attending\, you’ll be in the room with professionals from Takeda\, Regeneron\, Alexion\, Alnylam\, Merck\, Sanofi\, Sarepta Therapeutics\, Jazz Pharmaceuticals\, Beam Therapeutics\, Amylyx and more. \nAcross three days of workshops\, case studies\, panel discussions\, and networking\, gain practical insights into global access strategy\, post-trial access\, real-world data generation\, reimbursement transitions\, and regulatory intelligence while helping shape the future of Expanded Access Programs. \nDiscover the Full 2027 Agenda Here: https://ter.li/5w26qieq
URL:http://www.pharmajournalist.com/event/7th-operationalize-expanded-access-programs-summit/
LOCATION:Hilton Boston Park Plaza\, 50 Park Plaza\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20270323
DTEND;VALUE=DATE:20270326
DTSTAMP:20261112T125518Z
CREATED:20261112T125300Z
LAST-MODIFIED:20261112T125518Z
UID:44759-1805760000-1806019199@www.pharmajournalist.com
SUMMARY:10th Antigen-Specific Immune Tolerance Summit
DESCRIPTION:The 10th Antigen-Specific Immune Tolerance Summit returns to Boston this March\, bringing together the scientific\, clinical\, and industry leaders advancing antigen-specific therapies for autoimmune disease. \nAs leading programs generate pivotal clinical data and progress toward key development milestones\, the field is entering a new phase of clinical and commercial maturity. The meeting is designed to address the challenges most critical to developers of antigen-specific therapies\, including defining durable tolerance\, identifying meaningful biomarkers\, improving translational success\, optimizing antigen selection\, and generating the evidence needed to support regulatory and investment decisions. \nThe speaker faculty includes leaders from Diamyd Medical\, COUR Pharmaceuticals\, Parvus Therapeutics\, Eli Lilly & Co.\, Pfizer\, Bonsai Biotherapeutics\, and Boehringer Ingelheim\, alongside experts from academia\, investment\, and nonprofit organizations. Attendees will gain practical insights from both preclinical and clinical experience across autoimmune indications\, with discussions spanning development strategy\, biomarker selection\, trial design\, and commercialization pathways. \nView the full program to see what insights you can gain: https://ter.li/5tilo5ny \nKey sessions will explore clinically relevant biomarkers of tolerance\, the predictive value of preclinical models\, monitoring technologies for assessing therapeutic efficacy\, and the growing interest in combination approaches to achieve durable immune tolerance. Dedicated discussions on partnership and investment will also examine the evidence pharmaceutical companies and investors seek when evaluating emerging immune tolerance platforms. \nFor the first time\, the summit will take place as part of World Immune Tolerance Week\, alongside the 9th Treg-Directed Therapies Summit and the 2nd Immune Resetting: B-Cell Mediated & Beyond Summit. This co-located format provides broader visibility into complementary therapeutic approaches and opportunities to connect with decision-makers from across immunology\, autoimmune disease\, and precision medicine. \nSee what the previous attendees have to say: \n“It is truly the annual meeting in the ASIT field\, bringing together a community dedicated to sharing knowledge\, exchanging insights\, and celebrating the advances shaping the field”. \nChief Executive Officer\, Bonsai Biotherapeutics \n“As antigen-specific tolerance rapidly transitions from concept to clinic\, this summit stands out as a unique forum bridging immunology\, bioengineering\, and therapeutic development”. \nInstructor\, Division of Immunology & Rheumatology\, Stanford University \nCo-Founder & Scientific Advisor\, EBVio
URL:http://www.pharmajournalist.com/event/10th-antigen-specific-immune-tolerance-summit/
LOCATION:Hotel Commonwealth\, 500 Commonwealth Avenue\, Boston\, MA\, 02215\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR